anti-CD22 CAR NK cells

Anti-CD22 CAR NK cells are a form of cell therapy in which natural killer (NK) cells are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the CD22 antigen. CD22 is a transmembrane glycoprotein expressed on the surface of B-cell precursors and mature B-cells but lost during differentiation into plasma cells. The mechanism of action involves redirecting the cytotoxic activity of NK cells toward malignant B-cells expressing CD22, leading to targeted cell lysis. These therapies have shown promise in preclinical and early clinical studies for hematological malignancies such as B-cell lymphoma and B-cell acute lymphoblastic leukemia (B-ALL). Compared to CAR-T cell therapies, anti-CD22 CAR-NK cell therapies may offer advantages including lower risk of graft-versus-host disease and reduced cytokine release syndrome due to their shorter lifespan and less toxic cytokine production[1][4][6]. Some constructs use the m971 monoclonal antibody as the targeting domain within the CAR structure[4][6]. Early-phase clinical trials have demonstrated safety and preliminary efficacy in relapsed or refractory B-cell lymphoma[4], with ongoing research exploring their use in other cancers such as esophageal squamous cell carcinoma[1].

Other names

CD22-targeted CAR NK cellsCD-22-targeted CAR NK cellsCD 22-targeted CAR NK cellsCD22-redirected CAR NK-92 cellsCD-22-redirected CAR NK-92 cellsCD 22-redirected CAR NK-92 cellsm971-BBZ NK-92 cellsm-971-BBZ NK-92 cellsm 971-BBZ NK-92 cells